Back
to home » Treatment News » Top Stories
 July 27, 2006
|
An HIV Drug Says Goodbye
In a letter sent to doctors late last month, Roche Pharmaceuticals announced that it will be ending the sale and distribution of Hivid® (zalcitabine, also known as ddC), a nucleoside reverse transcriptase inhibitor (NRTI) originally approved in 1992.
|
|
|
July 24, 2006
|
I Forgot
Perfect adherence - taking medications as prescribed without missing doses - is considered to be one of the most important factors in terms of reducing the risk of HIV drug resistance and maximizing the life-saving benefits of treatment. But for many HIV-positive people taking daily doses, adherence can be a major challenge.
|
|
|
| July 20, 2006
|
July 18, 2006
|
Doctors, Patients Disagree on Resistance Concerns
HIV-positive people and their doctors agree that anti-HIV drug resistance is one of the most challenging issues in HIV care today. However, their degree of concern is dramatically different, according to a survey commissioned by the American Academy of HIV Medicine (AAHIVM).
|
|
|
July 12, 2006
|
One-Pill, Once-Daily Combo Approved
Bristol-Myers Squibb and Gilead Sciences announced on July 12 that they have received U.S. Food and Drug Administration (FDA) clearance to begin selling Atripla? (pronounced "uh-TRIP-luh"), their long-awaited fixed-dose combination tablet containing Sustiva® (efavirenz) and Truvada® (tenofovir and emtricitabine).
|
|
|
July 05, 2006
|
New Aptivus Warning: Bleeding in the Brain
he U.S. Food and Drug Administration announced on June 30 that it is working with Boehringer Ingelheim, the manufacturer of Aptivus® (tipranavir), to inform healthcare providers about a potentially serious health problem that has been in seen in patients taking the protease inhibitor.
|
|
|
|
|
|
 |
|
